Evidence map›Paper›PMID 25432751›Full record

ArticleMethods in enzymology2014

Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.

Katherine Deigan Warner, Adrian R Ferré-D'Amaré

Abstract read
In one paragraph

Article in Methods in enzymology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. X-Ray Crystallography to Study Conformational Changes in a TPP Riboswitch.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  2. SHAPE-enabled fragment-based ligand discovery for RNA.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katherine Deigan WarnerNational Heart, Lung and Blood Institute, Bethesda, Maryland, USA; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
Adrian R Ferré-D'AmaréNational Heart, Lung and Blood Institute, Bethesda, Maryland, USA. Electronic address: adrian.ferre@nih.gov.

Funding

RNA: Structure, Biophysics and PhysiologyZIAHL006102 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FERRÉ-D'AMARÉ, ADRIAN · 2011 to 2025
$14.6M
RNA: New Antimicrobial StrategiesZIAHL006150 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FERRÉ-D'AMARÉ, ADRIAN · 2012 to 2025
$11.8M
RNA: Tools for Cell BiologyZIAHL006188 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FERRÉ-D'AMARÉ, ADRIAN · 2014 to 2025
$9.5M
Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL006102Intramural NIH HHS ZIA HL006150Intramural NIH HHS ZIA HL006188
6 · The paper itself

Abstract

Riboswitches are structured mRNA elements that regulate gene expression in response to metabolite or second-messenger binding and are promising targets for drug discovery. Fragment-based drug discovery methods have identified weakly binding small molecule "fragments" that bind a thiamine pyrophosphate (TPP) riboswitch. However, these fragments require substantial chemical elaboration into more potent, drug-like molecules. Structure determination of the fragments bound to the riboswitch is the necessary next step. In this chapter, we describe the methods for co-crystallization and structure determination of fragment-bound TPP riboswitch structures. We focus on considerations for screening crystallization conditions across multiple crystal forms and provide guidance for building the fragment into the refined crystallographic model. These methods are broadly applicable for crystallographic analyses of any small molecules that bind structured RNAs.

Indexed as

RiboswitchBinding SitesCrystallography, X-RayDrug DiscoveryLigandsModels, MolecularSmall Molecule LibrariesThiamine PyrophosphateLigandsRiboswitchSmall Molecule LibrariesThiamine PyrophosphateFragment-based drug discoveryRiboswitchX-ray crystallography

Identifiers

PMID25432751
PMCPMC4274939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.